No company matches — see all tickers
Sanofi deal adds four new long-acting antibodies and settles Regeneron’s lawsuit over commercialization information and audit rights.
Schleifer and Yancopoulos’ one-time performance awards replace annual equity grants until 2036, tying payouts mainly to new-product revenue.
Dupixent collaboration income drove growth as combined EYLEA sales kept falling despite rapid EYLEA HD adoption.
Dupixent drove Sanofi collaboration growth; Development Balance repayment is expected to lift collaboration revenue from Q3.
Upfront and opt-in payments under collaboration and licensing deals drive an expected ≈$127M pre-tax acquired IPR&D charge.
Coverage: 10-K, 10-Q and 8-K filings filed since Jul 1, 2026.
Request longer coverage
Company data: Wikidata Q7308054
We read every message.
